ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Large Drop in Short Interest

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the target of a large drop in short interest in October. As of October 15th, there was short interest totalling 9,700 shares, a drop of 59.2% from the September 30th total of 23,800 shares. Approximately 0.9% of the company’s stock are sold short. Based on an average trading volume of 149,800 shares, the short-interest ratio is currently 0.1 days.

ZyVersa Therapeutics Stock Performance

Shares of NASDAQ:ZVSA opened at $2.10 on Friday. The stock’s fifty day simple moving average is $2.48 and its two-hundred day simple moving average is $3.87. ZyVersa Therapeutics has a 1-year low of $1.90 and a 1-year high of $42.70.

ZyVersa Therapeutics (NASDAQ:ZVSA) last announced its earnings results on Friday, August 9th. The company reported ($3.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($5.20) by $1.89. As a group, research analysts expect that ZyVersa Therapeutics will post -22.7 earnings per share for the current fiscal year.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.